Medical Advocates
Fostemsavir

Main Page

New and Noteworthy
Journal Data

ARV Investigational Drugs

Main New/Noteworthy

Home Page

Last Update: December 20, 2016
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

December 2016

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M, Lalezari JP, Kaplan R, Antivir Ther. 2016 Dec 6.

Journal Abstracts, Papers, and Commentaries

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Thompson M, Lalezari JP, Kaplan R
Antivir Ther. 2016 Dec 6.
Abstract

ARV Investigational Drugs

Main New/Noteworthy

Home Page

Fostemsavir